Evidence map›Paper›PMID 22174657›Full record

ArticleInternational journal of molecular sciences2011

In silico identification of structure requirement for novel thiazole and oxazole derivatives as potent fructose 1,6-bisphosphatase inhibitors.

Ming Hao, Xiaole Zhang, Hong Ren, Yan Li, Shuwei Zhang, Fang Luo, Mingjuan Ji, Guohui Li, Ling Yang

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Fructose 1,6-Bioscience reports · 2019
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ming HaoDepartment of Materials Science and Chemical Engineering, Dalian University of Technology, Dalian, Liaoning, 116023, China; E-Mails: dluthm@yeah.net (M.H.); zswei@dlut.edu.cn (S.Z.).
Xiaole Zhang
Hong Ren
Yan Li
Shuwei Zhang
Fang Luo
Mingjuan Ji
Guohui Li
Ling Yang

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fructose 1,6-bisphosphatase (FBPase) has been identified as a drug discovery target for lowering glucose in type 2 diabetes mellitus. In this study, a large series of 105 FBPase inhibitors were studied using a combinational method by 3D-QSAR, molecular docking and molecular dynamics simulations for a further improvement in potency. The optimal 3D models exhibit high statistical significance of the results, especially for the CoMFA results with r(ncv) (2), q(2) values of 0.986, 0.514 for internal validation, and r(pred) (2), r(m) (2) statistics of 0.902, 0.828 statistics for external validation. Graphic representation of the results, as contoured 3D coefficient plots, also provides a clue to the reasonable modification of molecules. (1) Substituents with a proper length and size at the C5 position of the thiazole core are required to enhance the potency; (2) A small and electron-withdrawing group at the C2 position linked to the thiazole core is likely to help increase the FBPase inhibition; (3) Substituent groups as hydrogen bond acceptors at the C2 position of the furan ring are favored. In addition, the agreement between 3D-QSAR, molecular docking and molecular dynamics simulation proves the rationality of the developed models. These results, we hope, may be helpful in designing novel and potential FBPase inhibitors.

Indexed as

Computer SimulationDiabetes Mellitus, Type 2Enzyme InhibitorsFructose-BisphosphataseHydrogen BondingModels, MolecularMolecular Docking SimulationMolecular Dynamics SimulationOxazolesQuantitative Structure-Activity RelationshipSequence AlignmentThiazolesEnzyme InhibitorsFructose-BisphosphataseOxazolesThiazoles3D-QSARCoMFACoMSIAFBPase inhibitorsmolecular dynamics

Identifiers

PMID22174657
PMCPMC3233463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.